Bill · H.R. 9190· House(119-HR-9190)
Right to Try for Individualized Treatments Act
- Introduced
- 6/8/2026
- Last activity
- 6/8/2026 — Referred to the House Committee on Energy and Commerce.
- Sponsored by
- Diana Harshbarger
- Cosponsors
- - 3 - 0
- Introduced
- In Committee
What this bill would do
The "Right to Try for Individualized Treatments Act" amends the Federal Food, Drug, and Cosmetic Act. It allows patients with life-threatening diseases, conditions, or severely debilitating illnesses to access investigational individualized medical treatments. These treatments are based on a patient's unique genomic profile. The bill defines eligible patients and the requirements for informed consent and physician certification. It also establishes the role of eligible health care facilities and manufacturers in providing these treatments.
Yes
Does this make health care easier to get in general?+7
Provides a legal pathway for patients with life-threatening conditions to access investigational genomic treatments.
Would people with disabilities be better off under this?+4
Provides potential access to genomic treatments for those with severely debilitating illnesses.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Access to Personalized Treatment: Patients with life-threatening diseases or severely debilitating illnesses may request investigational individualized medical treatments based on their unique genomic profile (Section 2(a)(1)(B) and 2(a)(4)).
-
Expanded Treatment Options: The bill allows eligible patients who have considered approved treatment options to seek these specific investigational treatments (Section 2(a)(1)(B)(ii)).
-
Clear Consent Process: The requirement for "additional informed consent" ensures patients receive an explanation of approved treatments, an identification of the recommended investigational treatment, and a description of potential outcomes (Section 2(a)(6)).
Potential Negative Impacts for People
- No Guarantee of Access: The bill explicitly states that a manufacturer of an investigational individualized medical treatment is not required to make the treatment available to any patient (Section 2(b)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Healthcare
- Improves Healthcare Access+7
- Demographic And Interest Groups
- Good For People With Disabilities+4
- 7/21/2026
- 1 Cosponsor added.
- 7/13/2026
- 1 Cosponsor added.
- 6/8/2026
- Referred to the House Committee on Energy and Commerce.
- 1 Cosponsor added.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Andy BiggsRepublican · Arizona
Paul GosarRepublican · Arizona
Abraham HamadehRepublican · Arizona